Category: Publications

Search News
Categories
Archives
Aggressive melanoma cells at edge of tumours are key to cancer spread

20th October 2020

Research led by Barts Cancer Institute, Queen Mary University of London, has revealed novel insights into the mechanisms employed by melanoma cells to form tumours at secondary sites around the body. The findings from the study may help to identify new targets to inhibit melanoma spread and guide treatment decisions in the clinic.

Read more

Novel insights into graft-versus-host disease

13th October 2020

Research led by Barts Cancer Institute, Queen Mary University of London, has identified a subset of immune cells involved in site-specific tissue damage in cancer patients who have developed harmful graft-versus-host disease after stem cell transplantation. The insights gained from the study may help to define new targets for more selective approaches to prevent or treat this condition in patients who have received a stem cell transplant.

Read more

Research explainer with Dr Gabriella Ficz

28th September 2020

We spoke with Dr Gabriela Ficz to find out about her recent publication in Nature Communications. The study set out to determine how embryonic stem cells can acquire features that are found in cancer cells.

Read more

Results from the Phase I STARPAC trial

24th September 2020

A treatment combination involving the addition of a form of vitamin A to the current standard treatment regimen for pancreatic cancer is safe for patients, according to an early phase clinical trial led by Professor Hemant Kocher from Barts Cancer Institute, Queen Mary University of London.

Read more

Immunotherapy for advanced bladder cancer

18th September 2020

An immunotherapy drug called ‘avelumab’ has been shown to significantly improve survival in patients with the most common type of bladder cancer, according to results from a phase III clinical trial led by Professor Tom Powles.

Read more

Investigating new treatment options for mesothelioma

16th September 2020

Results from a phase I clinical trial led by Professor Peter Szlosarek were recently published in JTO Clinical and Research Reports. The trial was investigating the safety and efficacy of a new drug combination for the treatment of mesothelioma. We spoke to Professor Szlosarek to find out more about the trial, and how the drug combination may be able to help patients with mesothelioma.

Read more

Search News
Categories
Archives